Market Overview

Don't Get Too Excited About Biogen's Q4 Earnings

Share:
Don't Get Too Excited About Biogen's Q4 Earnings

Baird Equity Research expects to see a “less-than-optimal Tecfidera performance” when Biogen Inc (NASDAQ: BIIB) issues its fourth-quarter earnings January 26.

The psoriasis treatment is predicted to fall short of sales revenue consensus by $45 million after scripts fell more than 6 percent year-over-year.

And the bad news doesn’t stop there.

Other Concerns Remain

According to Baird, Biogen lost ground in the multiple sclerosis market with a 28.5-percent share. Despite the fourth-quarter release of Zinbryta, the company suffered accelerated loss of scripts with figures signaling a year-over-year loss of 5.5 percent.

Nevertheless, the MS drugs are expected to meet consensus estimates, and Baird maintains optimism that Biogen could post a strong launch of Spinraza. In fact, Baird raised its Spinraza sales estimates from $102 million to $227 million based on the unanticipated addition of a sales quarter as well as the announcement of higher dosage costs.

“We're warming on the name as we expect earnings estimates for Spinraza to see some strong upward revisions over the next few quarters,” analysts wrote.

Biogen's product timeline includes a hemophilia segment in early February and a third-quarter launch of the immunosuppressive ocrelizumab.

Company shares have fallen steadily since November but were up 0.22 percent on the day at time of writing.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2019MaintainsHold
Jun 2019DowngradesOverweightNeutral
May 2019Initiates Coverage OnNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings News Health Care Previews Analyst Ratings Movers Best of Benzinga

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MUCascendReiterates65.0
ALDRCanaccord GenuityDowngrades20.0
LEGHLake StreetInitiates Coverage On21.0
CHUGoldman SachsUpgrades13.2
STZBMO CapitalMaintains230.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Trump Dump? Market Sells Off During Trump's Inauguration Speech

15 Biggest Mid-Day Losers For Friday